Diabetes drug shows promise for obesity after brain tumor therapy

NCT ID NCT02860923

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study tested whether exenatide, a diabetes medication, can help adults with severe weight gain caused by treatment for a rare brain tumor called craniopharyngioma. 42 participants received either exenatide or a placebo, along with lifestyle advice, for 6 months. The main goal was to see if exenatide leads to greater weight loss than placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTHALAMIC OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

APHM

Marseille, France
CHU d'Angers

Angers, France
CHU de Brest

Brest, France
CHU de Grenoble

Grenoble, France
CHU de Lyon

Lyon, France
CHU de Toulouse

Toulouse, France
Hôpital Bicêtre

Paris, France
Hôpital Cochin

Paris, France
Hôpital Européen Georges Pompidou

Paris, France
Hôpital Haut-Lévêque

Pessac, France
Hôpital Pitié Salpétrière (APHP)

Paris, France

Conditions

Explore the condition pages connected to this study.

CRANIOPHARYNGIOMAS HYPOTHALAMIC OBESITY